ASCO GU 2018: Hypoxia related mRNA biomarker to predict biochemical failure and metastasis for prostate cancer.
San Francisco, CA (UroToday.com) Dr. Choudhury and colleagues presented work on the development of a gene signature for hypoxia in prostate cancer (PC). Hypoxia is an important biological feature that appears to associate with the biological aggressiveness of PC tumors. For example, it is known that tumor hypoxia associates with radio-resistance, and some data also shows that it portends poor outcomes after prostatectomy, indicating that tumor hypoxia is an indicator of aggressive disease.
ASCO GU 2018: Review of First Presentation: SPARTAN and PROSPER
San Francisco, CA (UroToday.com) The management of metastatic prostate cancer (PCa) continues to change in rapid succession. While we were once reliant on androgen deprivation therapy (ADT) for hormone-sensitive prostate cancer (hsPCa) and docetaxel alone for the treatment of metastatic castration-resistant PCa (mCRPC), the landscape of PCa treatment has drastically changed. The introduction of androgen axis targeting agents, specifically enzalutamide (ENZA) and abiraterone (ABI), have revolutionized the field.
ASCO GU 2018: First Presentation - SPARTAN: A Study of Apalutamide (ARN-509) in Men with Non-Metastatic Castration-resistant Prostate Cancer
San Francisco, CA (UroToday.com) Dr. Eric Small provided the first presentation of the SPARTAN study results, another phase III, randomized double-blind controlled trial.
ASCO GU 2018: First Presentation - PROSPER: Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
San Francisco, CA (UroToday.com) Dr. Maha Hussain provided the first presentation of the phase III randomized double-blind controlled trial, the following men were eligible for inclusion:
ASCO GU 2018: Transcriptomic Heterogeneity of Androgen Receptor Activity in Primary Prostate Cancer: Identification and Characterization of a Low AR-active Subclass
San Francisco, CA (UroToday.com) Dr. Spratt presented original work from a cross-institutional collaborative effort studying androgen receptor signaling and activity. The androgen receptor (AR) is a key player in the pathogenesis of prostate cancer (PC). We now know that dysregulation and/or mutation of the AR gene correlates with significant differences in PC-related outcomes. AR signaling is involved in many important pathways (DNA signaling, immune modulation, etc…). AR amplifications/mutations are common (and often actionable), and it is also known that AR-activity (ARA) may play an important role in PC pathogenicity. Genomic analyses show that ARA is highly variable in patients with localized PC.
ASCO GU 2018: Medical Resource Utilization of Abiraterone Acetate Plus Prednisone added to ADT in Metastatic Castration-naive Prostate Cancer: Results from LATITUDE
San Francisco, CA (UroToday.com) The LATITUDE trial demonstrated that Abiraterone acetate and prednisone (AAP) + androgen deprivation therapy (ADT) exhibited significant improvements in overall survival (OS) and disease progression. The authors of this study aimed to assess event-driven medical resource utilization (MRU) from AAP + ADT vs ADT alone.
ASCO GU 2018: Management of Oligometastatic Prostate Cancer From Imaging to Therapy
San Francisco, CA (UroToday.com) Felix Feng, MD presented on the topic of the management of oligometastatic prostate cancer. Oligometastatic disease is an intermediate state of cancer spread between localized disease and widespread metastases. The advent and increased utilization of PET imaging has caused the space of oligometastatic disease to increase (Figure 1). PET imaging has been increasingly used to detect extra-pelvic disease in patients with PSA recurrences. Specifically, the increased usage of PSMA PET imaging has been demonstrated to increase diagnosis of oligometastatic disease.